Pharmedic (PMC) Faces Nationwide Recall of Eye Drops Over Quality Failure

Overview

Pharmedic (PMC), a pharmaceutical company listed on HOSE, had a batch of Natri clorid 0.9% eye drops recalled nationwide by the Drug Administration of Vietnam due to a quality failure in the clarity index. The recall, classified as level 3, adds to investor concerns as the stock has already fallen 33% from its peak. The company faces scrutiny over quality control, having been fined 70 million VND for a similar violation earlier this year.

Key Facts

• The Drug Administration of Vietnam ordered a nationwide recall of PMC’s Natri clorid 0.9% eye drops batch (registration number 893100060724, batch number 10370725).
• The batch was produced on July 14, 2025, and expires on January 14, 2028.
• The recall reason: failure to meet quality standards for the clarity index, classified as a level 3 violation.
• PMC requested customers to return all remaining stock of the affected batch.
• PMC’s stock (PMC) closed at 138,500 VND on the recall date, down 0.72% with low volume of 1,600 shares.
• The stock has declined approximately 33% from its peak of 184,000 VND in late December 2025.
• On January 21, 2025, PMC was fined 70 million VND for a similar quality violation.

What Happened

The Drug Administration of Vietnam issued a decision to recall a batch of Natri clorid 0.9% eye drops manufactured by Pharmedic (PMC). According to the testing facility, the batch failed the clarity index, a quality parameter. The recall is classified as level 3, indicating a moderate risk. PMC responded by issuing a notice to customers to return all remaining stock of the affected batch and stated it is investigating the root cause. The company emphasized that other batches of the same product remain in compliance with regulations.

At the recent shareholder meeting, a shareholder raised the issue of a previous fine of 70 million VND imposed on January 21 for a similar quality violation. Management attributed the incident to a supply chain issue rather than a manufacturing problem and stated it was promptly resolved.

Market Context

PMC shares closed at 138,500 VND on the day of the recall, down 0.72% on thin volume of 1,600 shares. The stock has been in a downtrend since late December 2025, when it hit a peak of 184,000 VND, representing a 33% decline. The broader pharmaceutical sector on HOSE has been relatively stable, but PMC’s quality issues may weigh on investor sentiment. The company’s market capitalization is approximately VND 12.9 trillion based on the current price.

Strategic Significance

The recall highlights quality control risks at PMC, which could erode trust in its products and brand. The company’s reliance on a single product line for a significant portion of revenue makes it vulnerable to such disruptions. The previous fine for a similar violation suggests systemic issues in quality management. For long-term investors, the incident raises questions about governance and operational oversight, particularly as the company targets modest revenue growth of 4% and a slight profit decline in 2026.

What to Watch

• PMC’s detailed explanation of the root cause and any corrective actions announced.
• Potential regulatory penalties or further recalls if additional batches are affected.
• Q2 2026 earnings release to assess financial impact from the recall and any sales loss.
• Any changes in market share for Natri clorid 0.9% eye drops following the recall.
• Investor reaction at the next shareholder meeting or any extraordinary general meeting.